Chemistry:Camizestrant
Camizestrant is an experimental medication that is being evaluated for the treatment of breast cancer.[1] It is an estrogen receptor alpha antagonist and a selective estrogen receptor degrader (SERD).[2]
Camizestrant is an oral selective estrogen receptor degrader (ngSERD) and complete estrogen receptor (ER) antagonist.[1] It blocks the activity of estrogen receptor alpha encoded by both wild-type and mutated ESR1 and induces proteasome-dependent degradation of estrogen receptor alpha, without agonizing estrogen receptor alpha.[1]
Society and culture
Legal status
In May 2026, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Etcamah, intended for the treatment of ER-positive, HER2-negative locally advanced or metastatic breast cancer in people with ESR1 gene mutations.[1] The applicant for this medicinal product is AstraZeneca AB.[1]
Names
Camizestrant is the international nonproprietary name.[3]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Etcamah EPAR". 22 May 2026. https://www.ema.europa.eu/en/medicines/human/EPAR/etcamah. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
- ↑ "Discovery of AZD9833, a Potent and Orally Bioavailable Selective Estrogen Receptor Degrader and Antagonist". Journal of Medicinal Chemistry 63 (23): 14530–14559. December 2020. doi:10.1021/acs.jmedchem.0c01163. PMID 32910656.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 87". WHO Drug Information 36 (1). 2022.
 |  |
